Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSD
Dates
study started
completion around

Description

Summary

This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as melphalan and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Thalidomide and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It is not yet known whether melphalan and prednisone are more effective when given together with thalidomide or lenalidomide in treating multiple myeloma.

Official Title

An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy

Details

Keywords

Multiple Myeloma, Plasma Cell Neoplasms, Thalidomide, Prednisone, Cortisone, Lenalidomide, Melphalan, Mechlorethamine, Nitrogen Mustard Compounds, Laboratory Biomarker Analysis, Quality-of-Life Assessment

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
Links
Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive.
ID
NCT00602641
Phase
Phase 3 Multiple Myeloma Research Study
Study Type
Interventional
Participants
About 306 people participating
Last Updated